---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-090461"
form_type: "8-K"
ticker: "DRIO"
cik: "0001533998"
company_name: "DarioHealth Corp."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:49:50.326176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C

## Summary
- Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).
- Net loss $18.0M vs $17.8M in Q2 2021; operating loss $17.4M; cash $68M.
- B2B2C contract value totals $55M; new national health plan deal providing reach to ~10M members.
- Strategic decision to reduce DTC focus and prioritize B2B2C channels, cutting customer acquisition costs 70%.
- Secured up to $50M non-dilutive credit facility with OrbiMed; on track to exceed 100 B2B2C contracts by year-end.

## SEC filing metadata
- accession: 0001104659-22-090461
- form_type: 8-K
- ticker: DRIO
- cik: 0001533998
- company_name: DarioHealth Corp.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/0001104659-22-090461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/tm2223436d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-090461
- JSON: https://secwatch.observer/filing/0001104659-22-090461.json
- Plain text: https://secwatch.observer/filing/0001104659-22-090461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.